A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: Study update
A. van Oosterom(European Organisation for Research and Treatment of Cancer), G. D. Demetri(Brigham and Women's Hospital), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Peter Reichardt(Helios Hospital Berlin-Buch), S. Drimitrijevic(Novartis (Switzerland)), A Yap(Novartis (Switzerland)), Jonathan A. Fletcher(Harvard University), Maria Dêbiec‐Rychter(Center for Human Genetics), N. Shand(Novartis (Switzerland)), Herlinde Dumez
Cited by 46
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k